According to a newly published market research report by 24LifeSciences, global drugs for schistosomiasis market was valued at USD 80.6 million in 2024 and is projected to reach USD 106.0 million by 2032, growing at a compound annual growth rate (CAGR) of 4.1% during the forecast period 2025–2032.

Schistosomiasis, commonly referred to as bilharzia or snail fever, is a neglected tropical disease caused by parasitic flatworms of the genus Schistosoma. These drugs target the parasite's lifecycle, with praziquantel being the first-line treatment due to its efficacy against all schistosome species. Other therapeutic options include oxamniquine (specifically for S. mansoni) and combination therapies under development. The established efficacy of these treatments continues to underpin their importance in global public health initiatives targeting tropical diseases.

Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/1732/drugs-for-schistosomiasis-market

Rising Global Burden of Schistosomiasis Fuels Market Growth

The increasing global prevalence of schistosomiasis, particularly in endemic regions, remains the primary growth driver for this market. With over 250 million people requiring preventive treatment annually and approximately 700 million people at risk worldwide, the demand for effective therapeutics continues to rise. Africa remains the most affected region, accounting for nearly 90% of global cases, with East Africa alone representing about 24% of the total market share. This high prevalence is driving governments and international organizations to increase funding for treatment programs, subsequently boosting the pharmaceutical market for schistosomiasis drugs.

In addition, the World Health Organization's roadmap for neglected tropical diseases aims to eliminate schistosomiasis as a public health problem in most endemic countries by 2030, ensuring a steady and recurring demand from healthcare settings worldwide.

Advancements in Pediatric Formulations Enhance Treatment Accessibility

Technological advancements in drug formulations have transformed the market by improving treatment accessibility, particularly for pediatric patients who represent over 50% of schistosomiasis cases. Recent developments include dispersible tablets and oral suspensions that improve treatment adherence in children. These innovations have strengthened treatment programs and enabled pharmaceutical manufacturers to address critical treatment gaps, supporting long-term market expansion.

Ongoing clinical research exploring novel therapeutic applications, including combination therapies and next-generation treatments, is further opening new growth avenues for the schistosomiasis drugs market.

Market Challenges: Limited Treatment Options and Distribution Barriers

Despite positive growth trends, the market faces notable challenges:

• Limited therapeutic options with overreliance on praziquantel

• Emerging drug resistance concerns in some endemic regions

• Logistical challenges in reaching remote endemic areas

• Cold chain storage requirements for some formulations

Additionally, regulatory complexities and funding uncertainties have introduced volatility that can deter long-term investments in drug development and manufacturing capacity expansion.

Get the Complete Report & Table of Contents: https://www.24lifesciences.com/drugs-for-schistosomiasis-market-1732

Africa Leads the Global Schistosomiasis Drugs Market

The African region, particularly East Africa, dominates the global schistosomiasis drugs market, accounting for approximately 24% of total market share. This leadership is driven by:

• Highest prevalence of schistosomiasis infections globally

• Strong focus on mass drug administration programs

• Growing healthcare infrastructure development

• Increasing international donor support and funding

Asia-Pacific and Latin America remain important emerging markets, supported by growing recognition of schistosomiasis burden and expanding control programs.

Public Health Programs Dominate Market by Distribution Channel

By distribution channel, public health programs represent the largest and most critical segment due to the mass drug administration nature of schistosomiasis treatment requiring organized healthcare infrastructure.
By drug type, praziquantel holds the dominant share owing to its broad-spectrum efficacy, WHO recommendation, and established safety profile across patient populations.

Competitive Landscape: Moderately Consolidated with Global and Regional Players

The global schistosomiasis drugs market is moderately consolidated, with the top players collectively accounting for significant market share. The competitive environment is shaped by manufacturing capabilities, regulatory compliance, distribution networks, and participation in global health initiatives.

Key companies profiled in the report include:

• Shin Poong Pharm

• Merck KGaA

• Bayer AG

• EIPICO

• Chandra Bhagat Pharma

• Taj Pharmaceuticals

• and More

Get the Complete Report & Table of Contents:
https://www.24lesciences.com/drugs-for-schistosomiasis-market-1732

Market Opportunities: Emerging Markets and Novel Therapeutics

Significant growth opportunities exist in emerging markets across Asia-Pacific and Latin America, supported by improving healthcare access and rising awareness of neglected tropical diseases. Furthermore, the development of novel therapeutic approaches, including combination therapies and next-generation treatments, is expected to generate new intellectual property and expand clinical adoption beyond the current standard of care.

Access the Full Report

Download a Free Sample Report (PDF):
https://www.24lifesciences.com/download-sample/1732/drugs-for-schistosomiasis-market

Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/drugs-for-schistosomiasis-market-1732

About 24LifeSciences

24LifeSciences is a leading provider of market intelligence and strategic research reports across pharmaceuticals, biotechnology, medical devices, and healthcare technologies. Our reports are designed to support data-driven decision-making for manufacturers, healthcare providers, investors, consultants, and policy makers worldwide.

Follow us on LinkedIn:
https://www.linkedin.com/company/lifesciences24/